Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00EEU
|
|||
Former ID |
DNC013415
|
|||
Drug Name |
Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
|
|||
Synonyms |
CHEMBL413827; Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2
Click to Show/Hide
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C59H92N16O12S
|
|||
Canonical SMILES |
CC(C)CC(C(=O)NC(CCSC)C(=O)N)NC(=O)CNC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CO)NC(=O)C(C)NC(=O)C3CCCN3C(=O)C(CCCCN)NC(=O)C4CCCN4C(=O)C(CCCN=C(N)N)N
|
|||
InChI |
1S/C59H92N16O12S/c1-35(2)30-42(52(81)69-40(49(62)78)24-29-88-4)68-48(77)33-66-51(80)43(31-37-16-7-5-8-17-37)71-53(82)44(32-38-18-9-6-10-19-38)72-54(83)45(34-76)73-50(79)36(3)67-55(84)46-22-15-28-75(46)58(87)41(21-11-12-25-60)70-56(85)47-23-14-27-74(47)57(86)39(61)20-13-26-65-59(63)64/h5-10,16-19,35-36,39-47,76H,11-15,20-34,60-61H2,1-4H3,(H2,62,78)(H,66,80)(H,67,84)(H,68,77)(H,69,81)(H,70,85)(H,71,82)(H,72,83)(H,73,79)(H4,63,64,65)/t36-,39-,40-,41-,42-,43-,44-,45-,46-,47-/m0/s1
|
|||
InChIKey |
HMZBUUAKDIVOFX-KWWDQKRUSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Substance-P receptor (TACR1) | Target Info | Inhibitor | [1] |
KEGG Pathway | Calcium signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Measles | ||||
Panther Pathway | CCKR signaling map ST | |||
Reactome | G alpha (q) signalling events | |||
WikiPathways | SIDS Susceptibility Pathways | |||
Gastrin-CREB signalling pathway via PKC and MAPK | ||||
Spinal Cord Injury | ||||
Peptide GPCRs | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.